VYRIPHARM BIOPHARMACEUTICALS ANNOUNCES THE HIRING OF DR. DAVID YANG TO SERVE AS THE COMPANY’S VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

Vyripharm Biopharmaceuticals today announced the hiring of Dr. David Yang as Vice President of Research and Development to the Company. In this role, Dr. Yang will aid the Company in working on various aspects of drug development and drug delivery system technologies as well as Vyripharm’s theranostic imaging platforms currently in development.

Dr. Yang brings to Vyripharm more than 30 years of pharmaceutical and fine chemicals experience. Dr. Yang received his B.S. degree in Pharmacy from Taipei Medical University in 1978. In 2007, Dr. Yang was promoted to Professor with tenure and also appointed to be the Chief of Radiotheranositc at the Division of Diagnostic Imaging at the University of Texas MD Anderson Cancer Center (UTMDACC). Dr. Yang’s research is involved in image-guided personalized treatment and prevention in cancers. Dr. Yang has mentored many clinic fellows, post-doctors, and UTGSBS students to their terminal Ph.D. degree. He received Distinguished Mentor Award for post-doctors in February, 2009 and Trainee Research Mentor Award by the MD Anderson Alumni and Faculty Association in May, 2010. He retired from UTMDACC in August, 2014, but holds the Consultant at the UTHSC, Houston, TX. At present, Dr. Yang is the Vice President for Vyripharm Biopharmaceuticals (Houston, TX). He also holds Visiting Professor both at the Department of Radiology in Yokohama City University in Japan and Taipei Medical University in Taiwan.

Dr. Yang is a premier drug development scientist with a long productive record of lucrative drug patents still yielding significant royalties at UTMDACC. He has authored 114 peer-reviewed publications, 52 patents, 14 invited reviews, one book, 24 book chapters and 306 abstracts. His research group is involved in developing technologies for identifying and eventually treating relapsed/ refractory cancers.

Elias Jackson Ph.D., Vyripharm’s President of Research and Development commented, “We are very happy to welcome Dr. Yang to the Vyripharm family. With his stellar reputation in drug development and pharmacology, he will prove to be invaluable in aiding Vyripharm to reach its ambitious product development goals in bringing high impact & low cost pharmaceuticals to market.”